TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase
Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or integrity
CleanScribe RNA Polymerase is a novel DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. During the IVT reaction, dsRNA can be produced as a byproduct, which can trigger undesirable inflammatory responses in host cells. The CleanScribe enzyme drastically reduces dsRNA formation during IVT by up to 85% compared to wild-type T7 RNA Polymerase.
“In this era of mRNA-based medicine, drug developers must streamline their supply chain to remain agile and keep up with demand,” said
CleanScribe RNA Polymerase provides researchers with a simple way to significantly reduce dsRNA in their IVT without compromising other important mRNA quality attributes. The product’s robustness, reproducibility, and dsRNA reduction make it ideal for mRNA synthesis, saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development for additional studies. It is also straightforward for researchers to integrate the enzyme into their IVT protocols without requiring extensive optimization.
“We’re thrilled to have had the opportunity to work with TriLink on the launch of CleanScribe RNA Polymerase,” shared
In addition to its newly launched CleanScribe RNA Polymerase, TriLink offers mRNA capping analogs (including the award-winning CleanCap® M6), mRNA raw materials (nucleotides and other IVT enzymes including wild-type T7 RNA polymerase), advanced scale-up capabilities, and unrivaled expertise in mRNA, oligonucleotide, and enzyme production. Leveraging more than 25 years of nucleic acid experience, TriLink is dedicated to advancing therapeutics, vaccines, and diagnostics by providing its customers with high-quality technology and chemistry and
To learn more about TriLink’s products and services, visit trilinkbiotech.com.
About TriLink BioTechnologies
TriLink BioTechnologies, a
About Alphazyme
About
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924933319/en/
Investor Contact:
+ 1 858-988-5917
ir@maravai.com
Media Contact:
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
Source: TriLink BioTechnologies